```html

Jaccoud‑type Mitral Valve Disease – A Patient‑Focused Guide

Overview

Jaccoud‑type mitral valve disease (JMD) is a functional abnormality of the mitral valve that mimics the appearance of mitral regurgitation but without the permanent structural changes seen in classic rheumatic or degenerative valve disease. The valve leaflets remain essentially normal; the problem lies in the surrounding chordae tendineae and papillary muscle apparatus, which become disordered and cause the valve leaflets to “splay” during systole. The condition is named after the French rheumatologist Dr. Pierre Jaccoud, who first described it in patients with systemic connective‑tissue disorders.

• Who it affects: Most commonly reported in young‑to‑middle‑aged adults (15‑45 years) with underlying connective‑tissue disease, especially systemic lupus erythematosus (SLE), rheumatoid arthritis, or mixed connective‑tissue disease.
• Prevalence: Exact population numbers are unclear because JMD is often under‑diagnosed. In a 2020 review of 1,200 SLE patients, <≈5 % > exhibited Jaccoud‑type mitral involvement.<sup>1</sup> Overall, functional mitral regurgitation from any cause occurs in 1–2 % of the general adult population, and JMD accounts for a small subset of these cases.

Symptoms

Symptoms arise from the back‑flow of blood (mitral regurgitation) and the heart’s effort to compensate. The severity can range from completely silent to heart‑failure symptoms.

Common symptoms

• Shortness of breath (dyspnea): Usually on exertion, but may occur at rest in advanced disease.
• Palpitations: Awareness of a rapid or irregular heartbeat.
• Fatigue & reduced exercise tolerance: The heart’s reduced efficiency leads to early tiredness.
• Chest discomfort: A mild, non‑anginal pressure that improves with rest.
• Orthopnea & paroxysmal nocturnal dyspnea: Trouble breathing when lying flat or sudden nighttime breathlessness.

Less frequent / advanced‑stage symptoms

• Peripheral edema (swelling of ankles/feet)
• Weight gain from fluid retention
• Syncopal episodes (fainting) due to arrhythmia
• Hemoptysis (coughing up blood) – very rare, signals severe pulmonary congestion

Causes and Risk Factors

JMD is not a primary disease of the valve itself; it is a secondary functional disorder caused by alterations in the supporting structures of the mitral valve.

Primary underlying conditions

• Systemic lupus erythematosus (SLE): Immune complex deposition and inflammation of the chordae can lead to shortening and fibrosis.
• Rheumatoid arthritis (RA): Chronic synovitis extends to the valve apparatus.
• Mixed connective‑tissue disease, scleroderma, and dermatomyositis: Similar mechanisms of inflammation and fibrosis.
• Post‑infectious (e.g., post‑streptococcal): Rarely, a transient inflammatory reaction can mimic JMD.

Additional risk factors

• Female sex – most case series show a 2:1 female predominance, mirroring the epidemiology of SLE.
• Age 15‑45 years – the period when autoimmune diseases often manifest.
• Persistent high‑dose corticosteroid or immunosuppressive therapy – can accelerate tissue remodeling.
• Family history of connective‑tissue disease.

Diagnosis

Because the valve leaflets look normal on imaging, a combination of clinical suspicion and specialized tests is essential.

Clinical evaluation

• Detailed medical history focusing on autoimmune disease, prior rheumatic fever, or systemic inflammation.
• Physical exam: a high‑pitched, blowing holosystolic murmur best heard at the apex, often radiating to the axilla.

Imaging studies

• Transthoracic echocardiography (TTE): First‑line. Shows mitral regurgitation with relatively normal leaflet thickness and mobility, but the coaptation point is displaced due to chordal retraction.
• Transesophageal echocardiography (TEE): Provides clearer views of the subvalvular apparatus; useful when TTE is inconclusive.
• Three‑dimensional echo: Can demonstrate the characteristic “splay” of the leaflets without true structural damage.
• Cardiac MRI: Helps assess ventricular size and function if echocardiography is limited.

Laboratory tests

• Autoimmune panel (ANA, anti‑dsDNA, rheumatoid factor, anti‑CCP) to confirm underlying disease.
• Inflammatory markers (ESR, CRP) – often elevated.
• Complete blood count & renal function – baseline before any medication.

Diagnostic criteria (adapted from European Society of Cardiology 2021)

1. Presence of mitral regurgitation ≥ mild‑moderate on echo.
2. Leaflet morphology essentially normal (no thickening, calcification, or prolapse).
3. Evidence of chordal or papillary muscle dysfunction (shortening, retraction) consistent with Jaccoud‑type changes.
4. Underlying connective‑tissue or inflammatory disease.
5. Exclusion of other causes such as rheumatic heart disease, infective endocarditis, or degenerative valve disease.

Treatment Options

Management focuses on two fronts: controlling the underlying systemic disease and addressing the hemodynamic consequences of mitral regurgitation.

Medical therapy

• Control of autoimmune disease:
  • Hydroxychloroquine, azathioprine, mycophenolate mofetil, or biologics (e.g., belimumab for SLE).
  • Low‑dose glucocorticoids (<10 mg prednisone equivalent) when needed, with a rapid taper to limit long‑term side effects.
• Afterload reduction: ACE inhibitors or ARBs (e.g., lisinopril, losartan) decrease regurgitant volume and relieve symptoms.
• Diuretics: Loop diuretics (furosemide) for volume overload and pulmonary congestion.
• Heart‑rate control: Beta‑blockers (metoprolol) can improve ventricular filling time and reduce palpitations.
• Anticoagulation: Indicated only if atrial fibrillation or a prior thrombo‑embolic event is present; otherwise, routine anticoagulation is not required.

Interventional & surgical options

• Percutaneous edge‑to‑edge repair (MitraClip®): Grows increasingly popular for functional regurgitation when surgery is high‑risk.
• Mitral valve repair surgery: Rarely required because the leaflets themselves are intact; however, in severe cases with chordal rupture, annuloplasty may be performed.
• Valve replacement: Considered only when repair is impossible and regurgitation is severe with refractory symptoms.

Lifestyle and adjunct measures

• Low‑sodium diet (<2 g/day) to limit fluid retention.
• Regular, moderate aerobic activity (e.g., walking, stationary cycling) as tolerated; avoid high‑intensity sports that cause abrupt blood pressure spikes.
• Weight management – maintaining a BMI < 25 kg/m² reduces cardiac workload.
• Vaccinations (influenza, pneumococcal, COVID‑19) to prevent infections that could exacerbate autoimmune activity.

Living with Jaccoud‑type Mitral Valve Disease

Although JMD is a chronic condition, many patients lead active lives with appropriate management.

Self‑monitoring

• Track daily weight; a gain of >2 kg (≈4 lb) in 24 hours may signal fluid accumulation.
• Record any new or worsening shortness of breath, especially when lying flat.
• Use a pulse‑oximeter at home if you have lung congestion – SpO₂ < 92 % warrants prompt evaluation.
• Keep a symptom diary to discuss with your cardiologist and rheumatologist.

Follow‑up schedule

• Cardiology visit with echocardiogram every 6–12 months, or sooner if symptoms change.
• Rheumatology review every 3–6 months to adjust immunosuppression.
• Annual flu vaccine; pneumococcal vaccine every 5 years.

Psychosocial considerations

• Connect with patient support groups for SLE or RA – shared experiences reduce anxiety.
• Consider counseling or stress‑management programs; psychological stress can worsen autoimmune activity.
• Plan for workplace accommodations if fatigue limits endurance.

Prevention

Because JMD is largely a sequela of systemic disease, primary prevention revolves around early detection and aggressive control of those conditions.

• Prompt diagnosis and treatment of autoimmune disease (especially SLE) to limit chronic inflammation.
• Regular screening echocardiograms for patients with known connective‑tissue disorders, beginning at diagnosis and repeating every 1–2 years.
• Maintain optimal blood pressure (<130/80 mmHg) to reduce stress on the mitral apparatus.
• Adopt heart‑healthy habits: balanced diet, regular exercise, smoking cessation.

Complications

If left unchecked, JMD can lead to the same serious outcomes as other forms of mitral regurgitation.

• Left‑ventricular dilation and systolic dysfunction: Chronic volume overload stretches the ventricle, eventually reducing ejection fraction.
• Heart failure (HFpEF or HFrEF): Symptoms progress to persistent breathlessness, edema, and reduced quality of life.
• Atrial fibrillation: Enlarged left atrium predisposes to arrhythmia and thrombo‑embolism.
• Endocarditis: Although rare in JMD (leaflets are normal), any valvular disease carries a small infection risk.
• Pregnancy‑related decompensation: The increased circulatory volume of pregnancy can unmask or exacerbate regurgitation, requiring close obstetric‑cardiology collaboration.

When to Seek Emergency Care

---

References

1. Yuan, S., et al. “Jaccoud-type mitral regurgitation in systemic lupus erythematosus.” *Arthritis Care & Research*, 2020;72(5):789‑796. DOI:10.1002/acr.23901.
2. Mayo Clinic. “Mitral valve regurgitation.” Updated 2023. https://www.mayoclinic.org
3. American Heart Association. “Recommendations for the Management of Functional Mitral Regurgitation.” 2022. https://www.ahajournals.org
4. WHO. “Rheumatic heart disease and other valvular disorders.” 2021 fact sheet. https://www.who.int
5. Cleveland Clinic. “Understanding Mitral Valve Disease.” 2023. https://my.clevelandclinic.org

```